(Q34612068)

English

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.

scientific article

Statements

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. (English)
Cornelia Winkelmann
Susanna Hegewisch-Becker

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit